Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines
Identifieur interne : 001723 ( Istex/Curation ); précédent : 001722; suivant : 001724Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines
Auteurs : Jia Wei [République populaire de Chine] ; Baorui Liu [République populaire de Chine] ; Lifeng Wang [République populaire de Chine] ; Xiaoping Qian [République populaire de Chine] ; Yitao Ding [République populaire de Chine] ; Lixia Yu [République populaire de Chine]Source :
- Cancer Chemotherapy and Pharmacology [ 0344-5704 ] ; 2007-10-01.
English descriptors
Abstract
Abstract: Purpose: Tetrandrine (Tet), a bis-benzylisoquinoline alkaloid that was isolated from the dried root of Hang-Fang-Chi (Stephania tetrandra S. Moore), is well known as processing a marked antitumor effect in vitro and in vivo. The aim of this study was to assess the interaction between tetrandrine and chemotherapeutic agents widely used in gastric cancer treatment, and to investigate the influence of tetrandrine on chemotherapeutic agent-associated gene expression and apoptosis. Methods: Synergistic interaction on human gastric cancer BGC-823 and MKN-28 cells was evaluated using the combination index (CI) method. The double staining with both Annexin-V-FITC and PI was employed to distinguish the apoptotic cells from living cells. Expression of chemotherapeutic agent-associated genes, i.e., excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS), class III β-tubulin (β-tubulin III) and tau, of BGC-823 cells with or without tetrandrine treatment were measured by real-time quantitative PCR. Results: Tetrandrine had a synergistic effect on the cytotoxicity of chemotherapeutic agents in both two gastric cancer cell lines. The combination of tetrandrine and chemotherapeutic agents could also induce apoptosis in a synergistic manner. Tetrandrine could suppress the mRNA expression of ERCC1, TS, β-tubulin III and tau. Most prominently, ERCC1, TS and β-tubulin III mRNA levels were markedly suppressed at 0.29-, 0.12- and 0.60-fold, respectively, by the presentation of tetrandrine. Conclusion: Tetrandrine appears a promising candidate for combining with three chemotherapeutic agents. The possible mechanisms might be the synergistic apoptotic effect and the downregulation of chemotherapeutic agent-associated genes.
Url:
DOI: 10.1007/s00280-007-0416-9
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001723
Links to Exploration step
ISTEX:441150D5EAA672682F9FEF0A54DCB93D61A070C5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines</title><author><name sortKey="Wei, Jia" sort="Wei, Jia" uniqKey="Wei J" first="Jia" last="Wei">Jia Wei</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>State Key Laboratory of Pharmaceutical Biotechnology, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Pharmaceutical Biotechnology, 210008, Nanjing</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Baorui" sort="Liu, Baorui" uniqKey="Liu B" first="Baorui" last="Liu">Baorui Liu</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: baoruiliu@nju.edu.cn</mods:affiliation><country wicri:rule="url">République populaire de Chine</country></affiliation></author><author><name sortKey="Wang, Lifeng" sort="Wang, Lifeng" uniqKey="Wang L" first="Lifeng" last="Wang">Lifeng Wang</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation></author><author><name sortKey="Qian, Xiaoping" sort="Qian, Xiaoping" uniqKey="Qian X" first="Xiaoping" last="Qian">Xiaoping Qian</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation></author><author><name sortKey="Ding, Yitao" sort="Ding, Yitao" uniqKey="Ding Y" first="Yitao" last="Ding">Yitao Ding</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation></author><author><name sortKey="Yu, Lixia" sort="Yu, Lixia" uniqKey="Yu L" first="Lixia" last="Yu">Lixia Yu</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>State Key Laboratory of Pharmaceutical Biotechnology, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Pharmaceutical Biotechnology, 210008, Nanjing</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:441150D5EAA672682F9FEF0A54DCB93D61A070C5</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1007/s00280-007-0416-9</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-LNSTR37H-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001723</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001723</idno><idno type="wicri:Area/Istex/Curation">001723</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines</title><author><name sortKey="Wei, Jia" sort="Wei, Jia" uniqKey="Wei J" first="Jia" last="Wei">Jia Wei</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>State Key Laboratory of Pharmaceutical Biotechnology, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Pharmaceutical Biotechnology, 210008, Nanjing</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Baorui" sort="Liu, Baorui" uniqKey="Liu B" first="Baorui" last="Liu">Baorui Liu</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: baoruiliu@nju.edu.cn</mods:affiliation><country wicri:rule="url">République populaire de Chine</country></affiliation></author><author><name sortKey="Wang, Lifeng" sort="Wang, Lifeng" uniqKey="Wang L" first="Lifeng" last="Wang">Lifeng Wang</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation></author><author><name sortKey="Qian, Xiaoping" sort="Qian, Xiaoping" uniqKey="Qian X" first="Xiaoping" last="Qian">Xiaoping Qian</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation></author><author><name sortKey="Ding, Yitao" sort="Ding, Yitao" uniqKey="Ding Y" first="Yitao" last="Ding">Yitao Ding</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation></author><author><name sortKey="Yu, Lixia" sort="Yu, Lixia" uniqKey="Yu L" first="Lixia" last="Yu">Lixia Yu</name><affiliation wicri:level="1"><mods:affiliation>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Oncology, Drum Tower Hospital Affiliated to Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, 210008, Nanjing</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>State Key Laboratory of Pharmaceutical Biotechnology, 210008, Nanjing, China</mods:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Pharmaceutical Biotechnology, 210008, Nanjing</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Cancer Chemotherapy and Pharmacology</title><title level="j" type="abbrev">Cancer Chemother Pharmacol</title><idno type="ISSN">0344-5704</idno><idno type="eISSN">1432-0843</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2007-10-01">2007-10-01</date><biblScope unit="volume">60</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="703">703</biblScope><biblScope unit="page" to="711">711</biblScope></imprint><idno type="ISSN">0344-5704</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0344-5704</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapeutic agents</term><term>Combination index</term><term>Gastric cancer</term><term>Synergy</term><term>Tetrandrine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Purpose: Tetrandrine (Tet), a bis-benzylisoquinoline alkaloid that was isolated from the dried root of Hang-Fang-Chi (Stephania tetrandra S. Moore), is well known as processing a marked antitumor effect in vitro and in vivo. The aim of this study was to assess the interaction between tetrandrine and chemotherapeutic agents widely used in gastric cancer treatment, and to investigate the influence of tetrandrine on chemotherapeutic agent-associated gene expression and apoptosis. Methods: Synergistic interaction on human gastric cancer BGC-823 and MKN-28 cells was evaluated using the combination index (CI) method. The double staining with both Annexin-V-FITC and PI was employed to distinguish the apoptotic cells from living cells. Expression of chemotherapeutic agent-associated genes, i.e., excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS), class III β-tubulin (β-tubulin III) and tau, of BGC-823 cells with or without tetrandrine treatment were measured by real-time quantitative PCR. Results: Tetrandrine had a synergistic effect on the cytotoxicity of chemotherapeutic agents in both two gastric cancer cell lines. The combination of tetrandrine and chemotherapeutic agents could also induce apoptosis in a synergistic manner. Tetrandrine could suppress the mRNA expression of ERCC1, TS, β-tubulin III and tau. Most prominently, ERCC1, TS and β-tubulin III mRNA levels were markedly suppressed at 0.29-, 0.12- and 0.60-fold, respectively, by the presentation of tetrandrine. Conclusion: Tetrandrine appears a promising candidate for combining with three chemotherapeutic agents. The possible mechanisms might be the synergistic apoptotic effect and the downregulation of chemotherapeutic agent-associated genes.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001723 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001723 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:441150D5EAA672682F9FEF0A54DCB93D61A070C5
|texte= Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines
}}
| This area was generated with Dilib version V0.6.33. |  |